HIK Hikma Pharmaceuticals Plc

 

TIDMHIK 
 
 
Hikma Pharmaceuticals Plc 
07 April 2010 
 
? 
 
 
 
Hikma and CellTrion enter an exclusive partnership agreement for biosimilars for 
                                the MENA Region 
=-Hikma acquires exclusive rights to large and distinct biosimilar portfolio 
comprised mainly of monoclonal antibodies - 
London, 7 April 2010: Hikma Pharmaceuticals PLC ("Hikma")(LSE: HIK, NASDAQ 
Dubai: HIK), the fast growing multinational pharmaceutical group, today 
announces that it has signed an agreement with South Korea-based Celltrion, Inc. 
and Celltrion Healthcare, Inc. ("Celltrion").  Under this agreement Hikma has 
the exclusive rights for the distribution and marketing of nine biosimilar 
products throughout the MENA region under its own brand.  These products are 
currently under development by Celltrion. The agreement also gives Hikma the 
ability to collaborate on the joint development and manufacture of the products 
for supply in the MENA region. 
Hikma has also signed a Product Supply Agreement with Celltrion for the first of 
the nine biosimilar products, for which an Investigational New Drug application 
("IND") has already been approved by various regulatory authorities, including 
EU countries. 
Hikma estimates that the total biologics market in the MENA region will reach 
$500 million in 2010. 
"Celltrion brings a history of expertise in the manufacturing of protein-based 
therapeutics," noted Said Darwazah, Chief Executive Officer of Hikma. "This 
partnership gives Hikma access to Celltrion's large biosimilar portfolio and is 
an excellent example of Hikma's commitment to developing its product portfolio 
through strong partnerships. We're excited to work with Celltrion and we look 
forward to expanding Hikma's presence in the MENA region with these significant 
biosimilars and to improving patient access to such critically needed 
therapies." 
"Hikma has the capabilities and experience in generic injectable pharmaceuticals 
required to sell biosimilars successfully in these important markets," said 
Jung-Sin Seo, CEO and Chairman of Celltrion Healthcare, Inc. and Celltrion, Inc. 
"We believe this partnership will benefit both companies by combining Hikma's 
broad outreach with Celltrion's advanced biologic manufacturing capabilities." 
=- ENDS -- 
 
 
Enquiries 
Hikma Pharmaceuticals PLC 
Susan Ringdal, Investor Relations Director          Tel: +44 (0)20 7399 2760 
 
Brunswick Group 
Jon Coles / Justine McIlroy                                          Tel: +44 
(0)20 7404 5959 
 
 
About Celltrion 
Celltrion, Inc. (www.celltrion.com/en/default.asp) is a leading 
biopharmaceutical company in Korea specialising in monoclonal antibody 
capabilities to develop, manufacture and distribute biologics that contribute to 
human life. Based on its world-class technology in monoclonal antibody 
manufacturing, Celltrion has entered into strategic collaborations with a number 
of global pharmaceutical companies. In addition, Celltrion is preparing an 
initiative involving the newly emerging world mAb biosimilars market with its 
advanced development technology and state-of-the-art facility, and is currently 
developing a large portfolio of biosimilars of blockbuster biologics. 
 
About Hikma 
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on 
developing, manufacturing and marketing a broad range of both branded and 
non-branded generic and in-licensed  products.  Hikma's operations are conducted 
through three businesses: "Branded", "Injectables" and "Generics" based 
principally in the Middle East and North Africa ("MENA") region, where it is a 
market leader, the United States and Europe.  In 2009, Hikma achieved revenues 
of $637 million and profit attributable to shareholders of $78 million.  For 
news and other information, please visit www.hikma.com. 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 NRAUGUCUCUPUGCQ 
 

Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024

Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024